Effect of fluoxetine and a low-carbohydrate diet on cardiometabolic risk markers in subjects at risk of diabetes mellitus
DOI:
https://doi.org/10.53591/rug.v132i1.1352Keywords:
Fluoxetine, Diet, Mellitus DiabetesAbstract
Background: Low carbohydrate diets are a good strategy to reduce weight, regulate insulin levels and anthropometric parameters in obese patients with an adverse cardiovascular profile. Objective: To determine the effect of fluoxetine, with a low carbohydrate diet in subjects at risk of diabetes mellitus. Materials and Methods: An observational and retrospective study was carried out, 162 medical records of the Nutrition Service at the University Hospital Guayaquil, were reviewed. 81 patients who followed a low carbohydrate diet <130 g / day and 81 patients with the same diet plus a daily dose of 40 mg of fluoxetine were selected. Anthropometric and biochemical parameters were evaluated at the beginning and 6 months after the intervention. For statistical analysis, the Wilcoxon test and the Wald-Wolfowitz test were applied. Results: The patients treated with a low-carbohydrate diet and fluoxetine had a significant decrease in weight (Δ = 5.85 kg; p <0.001), unlike the patients treated with a low-carbohydrate diet. Similar results were obtained when comparing BMI (Δ = 2.54 kg / m2; p <0.001), insulin (Δ = 2.62; p <0.001), HOMA-IR (Δ = 0.81; p < 0.001) and the metabolic values of cholesterol and glucose, (p <0.001). Conclusion Patients treated with fluoxetine and low carbohydrate diet improve cardio metabolic risk markers, in subjects at risk with diabetes mellitus.
References
World Health Organization. UN News. Urgent health challenges for the next decade according to WHO. Ginebra. OMS ;2010. Disponible en: https://teresaperez.net/2020/01/21/retos-de-salud-urgentes-para-la-proxima-decada-segun-la-oms/.
Van Vliet-Ostaptchouk JV, Nuotio M-L, Slagter SN, Doiron D, Fischer K, Foco L, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14(1):9. https://doi.org/10.1186/1472-6823-14-9.
Xi B, He D, Hu Y, Zhou D. Prevalence of metabolic syndrome and its influencing factors among the Chinese adults: the China health and nutrition survey in 2009. Prev Med (Baltim). 2013;57(6):867–71. https://doi. org/10.1016/j.ypmed.2013.09.023
Encuesta STEPS Ecuador 2018 MSP, INEC, OPS/OMS. Vigilancia de enfermedades no transmisibles y factores de riesgo. 2018. https://www.salud.gob.ec/wp-content/uploads/2020/10/INFORME-STEPS.pdf
Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med. 2008 Sep;121(9):748-57. Doi: 10.1016/j.amjmed.2008.03.046.
Steele, J.M., Urbina, E.M., Mazur, W.M. et al. Left atrial strain and diastolic function abnormalities in obese and type 2 diabetic adolescents and young adults. Cardiovasc Diabetol 19, 163 (2020). https://doi.org/10.1186/s12933-020-01139-9
Van der Valk ES, Savas M, van Rossum EFC. Stress and Obesity: Are There More Susceptible Individuals? Curr Obes Rep. 2018 Jun;7(2):193-203. Doi: 10.1007/s13679-018-0306-y.
Cortés Romero Celso Enrique, Escobar Noriega Alejandra, Cebada Ruiz Jorge, Soto Rodríguez Guadalupe, Bilbao Reboredo Tania, Vélez Pliego Marcela. Estrés y cortisol: implicaciones en la ingesta de alimento. Rev Cubana Invest Bioméd. 2018 ; 37(3): 1-15. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-03002018000300013&lng=es.
McElroy SL, Guerdjikova AI, Mori N, O'Melia AM. Pharmacological management of binge eating disorder: current and emerging treatment options. Ther Clin Risk Manag. 2012;8:219-41. Doi: 10.2147/TCRM.S25574.
Devlin MJ, Goldfein JA, Petkova E, Jiang H, Raizman PS, Wolk S, Mayer L, Carino J, Bellace D, Kamenetz C, Dobrow I, Walsh BT. Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. Obes Res. 2005 Jun;13(6):1077-88. Doi: 10.1038/oby.2005.126. PMID: 15976151.
Gorla K y Mathews M.Pharmacological Treatment of Eating Disorders. Psychiatry (Edgmont). 2005 Jun; 2(6): 43–48. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000192/
Díaz Anibal. Factores de riesgo cardiovascular y disfunción endotelial en adultos que viven a gran altura. Acta méd. Peru . 2016; 33(4): 289-295. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1728-59172016000400005&lng=es.
Beigi I, Moghisi F, Inzucchi S, Tiktin M. Standards Medical care in Diabetes. American Diabetes Association. 2012 March; 35(3). https://doi.org/10.2337/dc12-s011
Vega-López S, Venn BJ, Slavin JL. Relevance of the Glycemic Index and Glycemic Load for Body Weight, Diabetes, and Cardiovascular Disease. Nutrients. 2018 Sep 22;10(10):1361. Doi: 10.3390/nu10101361.
Tay J, Thompson CH, Brinkworth GD. Glycemic Variability: Assessing Glycemia Differently and the Implications for Dietary Management of Diabetes. Annu Rev Nutr. 2015;35:389-424. Doi: 10.1146/annurev-nutr-121214-104422.
Weigle DS, Breen PA, Matthys CC, Callahan HS, Meeuws KE, Burden VR, Purnell JQ. A high-protein diet induces sustained reductions in appetite, ad libitum caloric intake, and body weight despite compensatory changes in diurnal plasma leptin and ghrelin concentrations. Am J Clin Nutr. 2005 Jul;82(1):41-8. Doi: 10.1093/ajcn.82.1.41.
Fechner E, Bilet L, Peters HPF, Hiemstra H, Jacobs DM, Op 't Eyndt C,
Kornips E, Mensink RP, Schrauwen P. Effects of a whole diet approach on metabolic flexibility, insulin sensitivity and postprandial glucose responses in overweight and obese adults - A randomized controlled trial. Clin Nutr. 2020 Sep;39(9):2734-2742. Doi: 10.1016/j.clnu.2019.12.010.
Trumbo P, Schlicker S, Yates AA, Poos M; Food and Nutrition Board of the Institute of Medicine, The National Academies. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc. 2002 Nov;102(11):1621-30. Doi: 10.1016/s0002-8223(02)90346-9.
Rajabi S, Mazloom Z, Zamani A, Tabatabaee HR. Effect of low glycemic index diet versus metformin on metabolic syndrome. Int J Endocrinol Metab. 2015;13(4):e23091. https://doi.org/10.5812/ijem.23091
Goldenberg JZ, Day A, Brinkworth GD, Sato J, Yamada S, Jönsson T, Beardsley J, Johnson JA, Thabane L, Johnston BC. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ. 2021 Jan 13;372:m4743. doi: 10.1136/bmj.m4743.
Barber TM, Hanson P, Kabisch S, Pfeiffer AFH, Weickert MO. The Low-Carbohydrate Diet: Short-Term Metabolic Efficacy Versus Longer-Term Limitations. Nutrients. 2021 Apr 3;13(4):1187. doi: 10.3390/nu13041187.
Feinman R, Pogozelski W, Astrup A, Bernstein R, Fine EECWE. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. Nutrition. 2015 January; 31(1). Doi: 10.1016/j.nut.2014.06.011.
Organization WH. Reports of a WHO Consultation. [Online].; 2003 [cited 2020 agosto sabado. Available from: www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/
Shetty P, Kumanyika S. Waist Circumference and Waist-Hip Ratio. Report of a WHO Expert Consultation. 2010 January; 64(1). https://www.who.int/publications/i/item/9789241501491
Hernández Yero José Arturo, Tuero Iglesias Ángela, Vargas González David. Utilidad del índice HOMA-IR con una sola determinación de insulinemia para diagnosticar resistencia insulínica. Rev Cubana Endocrinol . 2011 ; 22(2): 69-77. Disponible en:
http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532011000200002&lng=es.
Feinman RD, Pogozelski WK, Astrup A, et al. La restricción de carbohidratos en la dieta como primer enfoque en el manejo de la diabetes: revisión crítica y base de evidencia . Nutrición 2015; 31 : 1-13. 10.1016 / j.nut.2014.06.011
Brinkworth G, Noakes M, Buckley J, Keogh J. Long-term effects of a very-low-carbohydrate weight loss diet compared with an isocaloric low-fat diet after 12 months. Am J Clin Nutr. 2009 July; 90(1). Doi: 10.3945/ajcn.2008.27326.
Napoleão, A.; Fernandes, L.; Miranda, C.; Marum, A.P. Effects of Calorie Restriction on Health Span and Insulin Resistance: Classic Calorie Restriction Diet vs. Ketosis-Inducing Diet. Nutrients 2021, 13, 1302. https://doi.org/10.3390/ nu13041302
Serralde-Zúñiga AE, Gonzalez Garay AG, Rodríguez-Carmona Y, Melendez G. Fluoxetina para adultos con sobrepeso u obesidad. Cochrane Database Syst Rev.2019 15 de octubre; 10 (10): CD011688. doi: 10.1002 / 14651858.CD011688.
Suplicy H, Boguszewski CL, Santos CM, Desterro de Figueiredo M, Cunha DR, Radominski R. A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. Int J Obes (Lond). 2014;38(8):1097-103. Doi:10.1038/ijo.2013.225
Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005 Apr 5;142(7):532-46. Doi: 10.7326/0003-4819-142-7-200504050-00012.
Guisado-Macías J, Méndez F, Baltasar I, Zamora F. Fluoxetina, topiramato y combinación de ambos en el control de la conducta alimentaria antes de la cirugía bariatrica. Actas Esp Psiquiatr. 2016; 44(3). Disponible en https://actaspsiquiatria.es/repositorio/18/101/ESP/18-101-ESP-93-6-683908.pdf
Hall KD, Chung ST. Low-carbohydrate diets for the treatment of obesity and type 2 diabetes. Curr Opin Clin Nutr Metab Care. 2018 Jul;21(4):308-312. Doi: 10.1097/MCO.0000000000000470.
Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP. Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr. 1991 Aug;54(2):321-5. Doi: 10.1093/ajcn/54.2.321.
Brouns F. Overweight and diabetes prevention: is a low-carbohydrate-high-fat diet recommendable? Eur J Nutr. 2018 Jun;57(4):1301-1312. Doi: 10.1007/s00394-018-1636-y.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0. International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes .
- NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
